Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 1/20 | 0.43 |
| ▸ | TPO | P07202 | 1/20 | 0.43 |
| ▸ | EPX | P11678 | 1/20 | 0.43 |
| ▸ | LPO | P22079 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.35 |
| ▸ | GABRP | O00591 | 1/20 | 0.35 |
| ▸ | GABRD | O14764 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL22395324 | 0.98 | MPO (0.42) | MPOTPOEPXLPOROCK1 | |
| SCHEMBL28979546 | 0.84 | MPO (0.41) | MPOTPOEPXLPOLTA4H | |
| SCHEMBL1000603 | 0.81 | NOS3 (0.46) | MPOTPOEPXLPOLTA4H | |
| Hydrochloric Acid SCHEMBL710140 | 0.79 | NOS3 (0.45) | MPOTPOEPXLPOLTA4H | |
| SCHEMBL24665317 | 0.77 | CHRNB2 (0.39) | ROCK1DRD1LMNAKMT2AMEN1 | |
| SCHEMBL30005327 | 0.77 | CHRNB2 (0.39) | ROCK1DRD1LMNAKMT2AMEN1 | |
| SCHEMBL30461582 | 0.76 | MPO (0.41) | MPOTPOEPXLPOLTA4H | |
| SCHEMBL28663680 | 0.76 | MPO (0.41) | MPOTPOEPXLPOLTA4H | |
| SCHEMBL21275802 | 0.76 | ROCK1 (0.41) | MPOROCK1MBOAT4DHFRDRD1 | |
| SCHEMBL12147787 | 0.75 | RXRA (0.41) | MBOAT4DRD1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12384773-B2 | Thiazole compounds and methods of use thereof | ARCUS BIOSCIENCES, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| WO-2025125665-A1 | FURTHER SUBSTITUTED IMIDAZOLES AS INHIBITORS OF NAV1.8 | Grünenthal GmbH (DE) | 2025-06-19 | — | — | WO | disclosed |
| US-20250145606-A1 | THIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2025-05-08 | — | — | US | disclosed |
| WO-2025096979-A1 | THIAZOLE COMPOUNDS AS KIT INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| CN-113754679-B | Substituted pyrimidinediones and their use | 广东东阳光药业有限公司 | 2023-04-07 | — | — | CN | disclosed |
| CN-113754679-A | Substituted pyrimidinediones and their use | 广东东阳光药业有限公司 | 2021-12-07 | — | — | CN | disclosed |
| US-10385012-B2 | Thioamides and amides for controlling animal pests | BASF SE (DE) | 2019-08-20 | — | — | US | disclosed |
| EP-3049396-B1 | PROCESS AND INTERMEDIATES FOR PREPARING INDANYLOXYDIHYDROBENZOFURANYL ACETIC ACID DERIVATIVES AS GPR40 AGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2017-11-15 | — | — | EP | disclosed |
| EP-2788086-B1 | SUBSTITUTED PYRAZOLES AS MGLU5 RECEPTOR MODULATORS | BOEHRINGER INGELHEIM INT (DE) | 2016-10-12 | — | — | EP | disclosed |
| CN-105431420-A | Diheteroaryl compounds and uses thereof | HOFFMANN LA ROCHE | 2016-03-23 | — | — | CN | disclosed |
| CN-104918934-A | 3-substituted pyrazoles and their use as DLK inhibitors | HOFFMANN LA ROCHE | 2015-09-16 | — | — | CN | disclosed |
| CN-104352492-A | Long-chain fatty acyl elongase inhibitor comprising arylsulfonyl derivative as active ingredient | MSD KK | 2015-02-18 | — | — | CN | disclosed |
| EP-2280001-B1 | LONG-CHAIN FATTY ACID ELONGATION ENZYME INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT | MSD KK (JP) | 2014-10-15 | — | — | EP | disclosed |
| CN-102015686-B | Novel heterocyclic compounds and uses therof | NOVARTIS AG | 2014-07-02 | — | — | CN | disclosed |
| US-8420823-B2 | Long-chain fatty acyl elongase inhibitor comprising arylsulfonyl derivative as active ingredient | MSD K.K. (JP) | 2013-04-16 | — | — | US | disclosed |
| CN-102015638-A | Long-chain fatty acid elongase inhibitor containing arylsulfonyl derivative as active ingredient | BANYU PHARMA CO LTD | 2011-04-13 | — | — | CN | disclosed |
| EP-2280001-A1 | LONG-CHAIN FATTY ACID ELONGATION ENZYME INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT | Banyu Pharmaceutical Co., Ltd. (JP) | 2011-02-02 | — | — | EP | disclosed |
| US-20110009622-A1 | LONG-CHAIN FATTY ACYL ELONGASE INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT | MSD K.K. (JP) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009622-A1 | LONG-CHAIN FATTY ACYL ELONGASE INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT | ELOVL1, ELOVL6, ELOVL3 | MPO 2730/4885TPO 3393/4885EPX 452/4885 |
| US-12384773-B2 | Thiazole compounds and methods of use thereof | TPMT, CYP11B2, ABAT | MPO 853/4885TPO 76/4885EPX 258/4885 |
| US-10385012-B2 | Thioamides and amides for controlling animal pests | TST, TMT1A, ACHE | MPO 2445/4885TPO 940/4885EPX 2077/4885 |
| US-20250145606-A1 | THIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | TPMT, CYP11B2, ABAT | MPO 853/4885TPO 76/4885EPX 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.